Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.62 |
| ▸ | CIT | O14578 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 2/20 | 0.62 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438774 | 0.83 | ROCK1 (0.66) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL439304 | 0.83 | ROCK1 (0.66) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887730 | 0.77 | ROCK1 (1.00) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL5924323 | 0.75 | ROCK1 (0.57) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL3254520 | 0.75 | ROCK1 (1.00) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887783 | 0.75 | ROCK1 (0.77) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL439622 | 0.74 | ROCK1 (0.55) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL5924416 | 0.74 | ROCK1 (0.75) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13895185 | 0.73 | ROCK1 (0.64) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL5924430 | 0.73 | ROCK1 (0.58) | ROCK1CYP3A4PRKACAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | ROCK1, ROCK2, RHOA | ROCK1 1/4885CYP3A4 3909/4885CIT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.